RxDoctor Payments Data

Kari Ring, MD

Gynecologic Oncology · Charlottesville, VANPI 1790949600

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,615 of the $13,867 with a category attached, or 83.8%. Medical Device Business Services, Inc. accounts for 73.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $12,260 and has fallen 90.9% since, to $1,115 in 2025.

$13,867in general payments, 2019–2025

Across 19 payments — averaging $729.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$10K
  • Ethicon Endo-surgery Inc.$3K
  • Johnson & Johnson$963
  • Medtronic$55
  • AstraZeneca$49
  • Genmab U.S., Inc.$35
$261,666in research payments, 2019–2025

Across 19 payments — averaging $13,772 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$262K

What the payments were for

  • Consulting fees$11,61584%
  • Travel & lodging$1,46411%
  • Food & beverage$7886%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,867 in reported general payments places this provider in the 85th percentile of 47 gynecologic oncology providers in Virginia.

See all gynecologic oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$56,401
Medicare patients
198
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$13,601
Letrozole24$354
Ondansetron Hcl11$336

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →